Quarterly report pursuant to Section 13 or 15(d)

Revenue - Revenue From Licensing Agreements and Strategic Partnerships (Details)

v3.20.2
Revenue - Revenue From Licensing Agreements and Strategic Partnerships (Details) - USD ($)
$ in Thousands
 3 Months Ended 6 Months Ended
Jun. 30, 2020
Jun. 30, 2019
Jun. 30, 2020
Jun. 30, 2019
Disaggregation of Revenue [Line Items]        
Total Revenue $ 11,246 $ 5,332 $ 24,507 $ 13,877
Seattle Genetics        
Disaggregation of Revenue [Line Items]        
Total Revenue 8,512 504 8,960 1,429
AstraZeneca        
Disaggregation of Revenue [Line Items]        
Total Revenue 2,334 3,888 5,045 9,908
Servier        
Disaggregation of Revenue [Line Items]        
Total Revenue $ 400 $ 940 $ 10,502 $ 2,540